🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/01/2022 135,00 138,15 135,00 135,87 +0,53% 2,33% 7.724.900
04/01/2022 135,33 136,22 134,38 135,16 -0,19% 1,36% 6.298.300
03/01/2022 135,41 135,70 133,51 135,42 +0,01% 1,62% 6.839.800
31/12/2021 136,04 136,21 135,30 135,40 -0,39% 0,67% 3.963.400
30/12/2021 135,75 136,83 135,63 135,93 +0,42% 0,88% 6.354.300
29/12/2021 134,61 135,87 134,08 135,36 +0,72% 1,33% 5.594.300
28/12/2021 134,55 135,26 133,74 134,39 -0,01% 1,13% 4.237.200
27/12/2021 133,19 134,48 133,16 134,41 +0,99% 0,99% 4.436.800
23/12/2021 132,33 133,77 132,17 133,09 +0,79% 1,21% 5.702.300
22/12/2021 129,91 132,58 129,78 132,05 +1,62% 2,16% 7.070.900
21/12/2021 131,23 131,35 129,15 129,95 -0,70% 1,68% 6.085.900
20/12/2021 128,51 131,39 128,23 130,86 +1,03% 2,46% 7.119.200
17/12/2021 130,84 131,02 129,37 129,53 -1,71% 1,26% 12.631.100
16/12/2021 130,10 133,28 129,91 131,78 +1,19% 2,59% 9.569.000
15/12/2021 128,25 130,78 127,60 130,23 +2,31% 2,48% 9.585.600
14/12/2021 125,70 127,85 125,38 127,29 +0,62% 1,96% 6.381.400
13/12/2021 125,20 127,74 125,20 126,51 +0,83% 2,03% 7.834.200
10/12/2021 123,72 126,01 123,72 125,47 +1,06% 1,85% 7.059.500
09/12/2021 122,21 124,46 122,10 124,15 +1,87% 1,93% 8.082.300
08/12/2021 121,96 122,44 120,75 121,87 +0,30% 1,39% 5.278.100
07/12/2021 121,98 122,14 121,00 121,51 +0,13% 0,93% 6.123.300
06/12/2021 119,63 122,45 119,21 121,35 +2,10% 2,71% 8.939.900
03/12/2021 117,74 119,00 117,00 118,85 +1,69% 1,70% 6.428.100
02/12/2021 116,25 117,60 115,60 116,87 +0,83% 1,72% 4.919.800
01/12/2021 115,78 118,98 115,61 115,91 +0,55% 2,91% 6.287.500
30/11/2021 116,68 116,79 115,10 115,28 -1,38% 1,45% 8.172.100
29/11/2021 116,83 117,92 116,58 116,89 +0,33% 1,15% 4.372.500
26/11/2021 117,61 118,11 115,83 116,51 -1,81% 1,94% 5.016.700
24/11/2021 118,68 119,24 118,08 118,66 -0,19% 0,98% 5.792.800
23/11/2021 116,56 119,33 116,15 118,88 +2,79% 2,73% 8.948.300